MetrioPharm announces Thomas Christély as incoming CEO alongside Dr. Wolfgang Brysch remaining as CSO and CMO

– SWITZERLAND, Zurich –  MetrioPharm AG, a pharmaceutical company developing drugs for chronic inflammatory diseases, today announced the appointment of Thomas Christély as CEO, effective October 1, 2021, to replace co-founder and co-owner, Dr. Wolfgang Brysch who will continue in his role of Chief Scientific Officer and Chief Medical Officer.

“I am very pleased to welcome Thomas Christély to the company. With his profound experience in business development, he is extremely well suited to prepare the company for the next milestones. The new management structure will allow us to build on our excellent clinical work while enforcing our company’s growth.” said Board Chairman, Rudolf Stäger.

He added: “On behalf of the entire Board of Directors, I would like to thank Dr. Wolfgang Brysch for the excellent positioning of MetrioPharm AG until today, which has just been confirmed by the European Commission’s nomination to the list of HERA funded projects.”

The future responsibilities of Thomas Christély at MetrioPharm will include most notably business development and financing, while Dr. Brysch will lead the future expansion of the development pipeline for the company’s lead compound MP1032, in addition to the Phase II study in the indication COVID-19.

Dr. Wolfgang Brysch said: “As CSO and CMO, I will be able to fully focus on the scientific strategy and medical development of our lead compound in the future. Our goal is to rapidly bring MP1032 to market while simultaneously developing its full potential in additional indications. I am very much looking forward to intensifying the corporate growth of MetrioPharm AG together with Thomas Christély.”

About Thomas Christély

Thomas Christély has comprehensive experience in the biotech and pharma industry as CEO, CFO, and CBO in Europe and the US; he has successfully concluded more than 20 significant collaborations and licensing agreements with major international pharma and biotech companies, including AstraZeneca, Pfizer, and Novartis. Most recently, as Managing Director and CFO, he led the successful development of the German pharmaceutical start-up MYR GmbH; in this role, he was responsible for the sale of the company to Gilead Sciences Inc. in a transaction worth €1.15 billion-plus a milestone payment of a further €300 million.

About MetrioPharm AG

MetrioPharm AG is a pharmaceutical development company focusing on drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. We hope to achieve a healthspan expansion for patients: We want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people.

MetrioPharm was founded in 2007 with headquarters in Zurich. The company has its R&D activities in Berlin.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team